RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsNew ADC payload mechanisms
What differentiates next-generation ADCs from those currently on the market is the incorporation of novel features including site-specific conjugation, new payload mechanisms and new antibody formats.
The success of Enhertu is serving as a driver of next-gen ADCs development.
Enhertu is basically an old antibody with an old linker with a different payload,”. “That payload made a huge difference.”
Experts caution that there are challenges with ADCs that still need to be overcome, including toxicities and the tumor microenvironment (TME) itself.
ONCY's pelareorep can be incorporated into an exisiting ADC as a new payload, and since pelareorep has demonstrated to remodel an otherwise immunosuppressive tumor microenvironment (TME), an immune checkpoint inhibitor can be subsequently added to the combination to synergistically improve treatment effectiveness in multiple cancers, while also reducing current ADC toxicity issues.